The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc
Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in
Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan
Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.